Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) insider Anne Evans Kingston sold 7,662 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $8.47, for a total value of $64,897.14. Following the transaction, the insider owned 55,782 shares of the company’s stock, valued at $472,473.54. This trade represents a 12.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Prothena Stock Performance
PRTA opened at $8.41 on Friday. The stock’s 50 day moving average price is $9.09 and its 200-day moving average price is $9.43. Prothena Corporation plc has a one year low of $6.61 and a one year high of $11.80. The stock has a market cap of $440.26 million, a price-to-earnings ratio of -2.98, a P/E/G ratio of 1.37 and a beta of -0.31.
Prothena (NASDAQ:PRTA – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.91. Prothena had a negative return on equity of 43.44% and a negative net margin of 260.92%.The firm had revenue of $51.08 million during the quarter, compared to analyst estimates of $0.81 million. As a group, analysts predict that Prothena Corporation plc will post 0.18 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on Prothena
Hedge Funds Weigh In On Prothena
A number of large investors have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. lifted its holdings in Prothena by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 90,795 shares of the biotechnology company’s stock worth $889,000 after buying an additional 2,251 shares during the period. ADAR1 Capital Management LLC boosted its position in Prothena by 8.5% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,581,443 shares of the biotechnology company’s stock valued at $15,372,000 after acquiring an additional 123,679 shares in the last quarter. Rubric Capital Management LP increased its holdings in shares of Prothena by 36.0% in the 1st quarter. Rubric Capital Management LP now owns 5,000,000 shares of the biotechnology company’s stock valued at $48,600,000 after acquiring an additional 1,322,669 shares during the period. Quantinno Capital Management LP increased its holdings in shares of Prothena by 39.3% in the 1st quarter. Quantinno Capital Management LP now owns 144,299 shares of the biotechnology company’s stock valued at $1,403,000 after acquiring an additional 40,681 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Prothena by 39.5% in the 1st quarter. Renaissance Technologies LLC now owns 607,515 shares of the biotechnology company’s stock worth $5,905,000 after acquiring an additional 172,000 shares in the last quarter. Institutional investors own 97.08% of the company’s stock.
Prothena Company Profile
Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.
The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.
Featured Articles
- Five stocks we like better than Prothena
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
